Phytochemical-based Nanoformulations to Tackle Drug Resistance in Cancer.

boost the phytochemical bioavailability to local tumours as well lower the chances that neighbouring or distant organs would have unfavourable side effects.Singh et al offer an insightful overview of Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer, with a focus on therapeutic advancements such as the usage of nanotechnological interventions. To overcome drug resistance and limited efficacy in current treatment options, nano formulations can be used in patients with HER2+ BC treatment. Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors.Another interesting advancement has been the popularization of network pharmacology as an approach to screen new therapeutic targets and moieties. The research work shared by Ahmed et al sheds light on the exploration of MARK4 as a target for the management of hepatocellular carcinoma, with the role played by phytoconstituents in regulating expression of proteins and interactions with altered genes.An intriguing study by Upadhyay et al focuses on the therapeutic potentials of yeast-derived β-1,3-glucan particles in cervical cancer amelioration, as a safe and effective approach. With time, a need to explore alternative therapeutic strategies has been felt, to improve therapeutic outcomes and the quality of life of patients. Using instrumental techniques, the authors characterised the particles and established an effective concentration for dosing. The authors also highlight the need for further research, in order to develop a deeper understanding of the spectrum of actions and potentials for clinical usage of the agent studied.The review article by Sindhoor et al investigates the role of alkaloidal nanoformulations for lung cancer therapy, as an approach to tackle commonly associated problems with the delivery of The review explores the mechanism of different alkaloids with reference to the pathways targeted, drawbacks associated with conventional treatment strategies, as well as highlighting the need for nanoformulations, moving forward. Kaur et al analyse the efficacy of a Frankincense oil-loaded nanoemulsion formulation of paclitaxel and erucin, in a study focused on drug resistance in breast cancer. The study explores the rationale of selection of the constituents, signalling pathways targeted, as well as studies from evaluation in an animal model, to elucidate the synergistic role of the actives in overcoming drug resistance. The study offers an in-depth overview of the formulation considerations and due modulations, effects on various biomarkers and prospects for further research and development.Singh et al explore the domain of Ehrlich-ascites carcinoma, proposing the development and usage of nanoparticles loaded with erucin, a dietary isothiocyanate isolated from Eruca sativa.The authors discuss the antioxidant property of the phytoconstituent, established using a variety of in vitro assay techniques, and effects on cellular proliferation. A novel approach to erucin delivery, through the designing of cubosomes, has been elucidated, which shall pave the way for further advancements and applications in clinical settings. We sincerely hope you enjoy reading this collection of articles, which was written on a subject that is likely to become even more decisive in the upcoming years.